Cassava Sciences Inc vs Uranium Energy Corp — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Uranium Energy Corp trades at $11.4 (market cap $5.67B). The key difference: Uranium Energy Corp is far larger — about 118.7× Cassava Sciences Inc's market cap, and Uranium Energy Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | UEC | |
|---|---|---|
Market Cap | $47.75M | $5.67B |
Sector | Health | Energy |
52-Week High | $4.64 | $20.14 |
52-Week Low | $0.87 | $9.04 |
Enterprise Value | -$34.93M | $5.18B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
UEC trades at $11.64, up 2.28% today, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025 despite $66.84 million revenue, with negative profit margins and cash flow challenges. Recent news highlights insider selling and ongoing uranium market optimism. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals show significant financial strain.
UEC presents high-risk exposure to uranium market growth with substantial operational losses and negative cash flow from operations. The stock's premium valuation (P/S 267.84) relies heavily on future nuclear energy adoption, while current financials indicate dependency on financing activities. Near-term catalysts include production ramp-up and licensing approvals, but execution risks and cost pressures remain elevated.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →